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Background: Since 2001 we have utilized a novel surgical approach for Pancoast tumors in which lobectomy and
mediastinal lymph node dissection are performed directly though the chest wall defect. The defect is then patched
at the completion of the procedure (“cut-in patch-out”) thereby avoiding a separate thoracotomy with rib spreading.
We undertook a study to compare outcomes of this novel “cut-in patch-out” technique with traditional thoracotomy
for patients with Pancoast tumors.
Methods: We retrospectively identified 41 patients undergoing surgical resection of Pancoast tumors requiring en-bloc
removal of at least 3 ribs at our institution from 1999 to 2012. Surgery was accomplished by either a “cut-in patch-out”
technique (n = 25) or traditional posterolateral thoracotomy and separate chest wall resection (n = 16). Multiple variables
including patient demographics, neoadjuvant therapy, extent of resection, and pathology were analyzed with respect
to outcomes from morbidity, narcotic use, and oncologic perspectives.
Results: Baseline demographics, neoadjuvant therapy, and perioperative factors including extent of surgery, complete
resections (R0), nodal status and lymph node number, morbidity, and mortality were similar between the two groups.
The mean duration of out-patient narcotic use was significantly lower in the “cut-in patch-out” group compared to the
thoracotomy group (80.6 days ± 62.4 vs. 158.2 days ± 119.2, p < 0.01). Using multivariate regression analysis, the
traditional thoracotomy technique (OR 7.72; p = 0.01) was independently associated with prolonged oral narcotic
requirements (>100 days). Additionally, five year survival for the “cut-in patch-out” group was 48% versus the traditional
group at 12.5% (p = 0.04).
Conclusions: Compared with a traditional thoracotomy and separate chest wall resection approach for P-NSCLC, a
“cut-in patch-out” technique offers an alternative approach that appears to have at least oncologic equivalence while
decreasing pain. We have more recently adapted this technique to select patients with pulmonary neoplasms involving
chest wall invasion and believe further investigation is warranted.
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Although initially characterized by a radiologist, Henry
Pancoast, in 1924, surgical resection of a superior sulcus
or Pancoast tumor was not attempted until the 1950s
[1,2]. It is estimated that 5% of all non-small cell lung
cancers (NSCLCs) require chest wall resection with* Correspondence: kkesler@iupui.edu
1Division of Cardiothoracic Surgery, Department of Surgery, Indiana
University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA
3Department of Surgery, Cardiothoracic Division, Indiana University School of
Medicine, 545 Barnhill Dr, Emerson Hall 215, Indianapolis, IN 46202, USA
Full list of author information is available at the end of the article
© 2014 Weber et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.approximately 20% of these cases considered to be
Pancoast tumors (P-NSCLC) involving the apical ribs
[3]. Current recommendations for P-NSCLC patients
with localized disease include neoadjuvant chemoradia-
tion therapy followed by surgical resection [4]. Surgery
for P-NSCLC is particularly challenging. Traditionally, a
posterolateral thoracotomy has been initially performed
to both divide pulmonary hilar structures and perform
mediastinal lymph node dissection followed by resection
of the involved chest wall [5]. It has been well estab-
lished however that significant morbidity can be associ-
ated with rib spreading during thoracotomy includingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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longed return of functionality [6-8]. Such concerns are
further compounded for those patients undergoing sur-
gery for P-NSCLC tumors who require a chest wall re-
section in addition to a thoracotomy. It is therefore not
surprising that P-NSCLC patients often experience post-
operative pulmonary complications as well as require
prolonged narcotic requirement for pain management.
Since 2001 we have utilized a novel surgical approach
for P-NSCLC requiring en-bloc removal of at least 3
ribs where lobectomy and mediastinal lymph node dis-
section are performed though the defect after chest wall
resection. The defect is patched at the completion of
the procedure (“cut-in patch-out”) thereby avoiding a
separate thoracotomy with rib spreading. The aim of
this study was to compare short and long term out-
comes between P-NSCLC patients undergoing this novel




Under the Indiana University School of Medicine Institu-
tional Review Board approval, a query of an institutional
database was undertaken. Forty-one patients undergo-
ing surgical resection of a P-NSCLC requiring en-bloc
removal of at least 3 ribs from 1999 to 2012 were iden-
tified. Since 2001, 25 patients were identified who un-
derwent a novel “cut-in patch-out” approach. Sixteen
patients underwent resection of a P-NSCLC by a trad-
itional posterolateral thoracotomy and separate chest
wall resection who served as controls. Patients with
anterior based apical tumors requiring a partial ster-
notomy approach (n = 6) and P-NSCLC who required
en bloc removal of only 2 or fewer ribs (n = 13) were
excluded from this study.
Patient demographic data including age, gender, neoad-
juvant chemotherapy/radiation therapy, and co-morbidities
were collected. Operative and pathologic variables includ-
ing tumor size, histology, stage, number of ribs resected,
estimated blood loss, type of surgical resection (R0, R1,
and R2), and number of mediastinal lymph nodes har-
vested were collected. Short term post-operative data in-
cluding duration of intravenous narcotics, length of
hospital stay, morbidity (pulmonary and non-pulmonary
morbidity) and mortality were recorded. Survival data
was verified with the Social Security Death Index. Long-
term postoperative data including duration of daily nar-
cotic use following discharge were collected and verified
by a statewide narcotic tracking system. This system,
under the auspices of the state government, provides an
online database of all prescribed controlled substances,
including narcotics. Finally, status at time of last follow
up was obtained.Operative procedure
All surgery was performed at Indiana University Melvin
and Bren Simon Cancer Center. Traditional resections
were performed through an extended poster lateral
thoracotomy incision with a separate chest wall resec-
tion as described by Paulson and Shaw [9]. These proce-
dures typically involved a 5th interspace thoracotomy
with rib spreading for hilar dissection and lobectomy
along with complete peribronchial and mediastinal
lymph node dissection. Apical en bloc chest wall resec-
tion was typically accomplished after hilar dissection
in these cases. After 2001, a majority of patients with
P-NSCLC underwent resection using a “cut-in patch-
out” technique which did not involve a separate thoracot-
omy. With the “cut-in patch-out” technique, an extended
posterolateral incision was also utilized. In these cases
however, the pleural space was initially entered in the
interspace estimated to be 3 to 5 cm anterior and inferior
to the tumor location, as determined by preoperative CT
scan. The tumor was palpated and, if clear of the inter-
space entry site, the interspace was opened posteriorly to
the costovertebral angle. The anterior aspect of the chest
resection was then performed 3 to 5 cm anterior to the
tumor location, again confirmed visually or by palpation.
A one cm segment of rib was excised anteriorly to im-
prove chest wall mobility which was facilitated by upward
scapular retraction (Figure 1). The superior border of the
resection was established at the level of the first inter-
space if the first rib could be spared or more commonly,
the soft tissues superior up to the first rib including sca-
lene muscles with careful attention to spare the sub-
clavian vessels and brachial plexus when oncologically
feasible. Also when possible, the T1 nerve root to the
lower trunk of the brachial plexus was also spared to
maintain ulnar nerve function. The ribs were then disar-
ticulated posteriorly from their respective transverse
processes and vertebral bodies carefully occluding inter-
costal vessels and nerves when encountered. After chest
wall resection was complete, lobectomy and peribron-
chial and mediastinal lymph node dissections were per-
formed through the chest wall defect itself (Figure 2).
Ligation and division of hilar structures was facilitated
with the use of endoscopic stapling devices designed for
thoracoscopic lobectomy. Commonly the stapling devices
were placed through the chest wall defect itself although
occasionally if the chest wall defect was limited, a separ-
ate small incision in the inferior chest was necessary for
stapler application. After the specimens are removed, the
chest wall defect was closed with a double layer of a
Vicryl mesh (Ethicon Inc, Somerville, NJ) (Figure 3).
Mesh was secured to the transverse processes and then to
the rib edges and with interrupted 0-polyproplene sutures
and reinforced with a running looped 0-polydioxanone
suture. In both approaches, two standard chest tube
Figure 1 The “cut-in patch-out” technique. The pleural space is initially entered in the lowest tumor free interspace typically 3 to 5 cm anterior
and inferior to the tumor location, as determined by preoperative CT scan, then extended posteriorly. The anterior aspect of the chest resection
was then performed 3 to 5 cm anterior to the tumor location facilitated by upward scapular retraction. A one cm segment of rib is excised
anteriorly to improve chest wall mobility.
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space. Additionally a soft tissue drain was typically placed
between the Vicryl mesh and scapula.
Statistical analysis
All statistical analysis was performed with Statistical
Package for the Social Science (SPSS, Chicago, IL) ver-
sion 20.0 for Windows. Values are presented as means
with standard deviations unless otherwise specified. Con-
tinuous variables were compared using student t-test while
categorical variables were compared with the chi squared.
Survival and recurrence analysis was performed using the
Kaplan-Meier method. A multivariate regression analysis
for prolonged duration of oral narcotics (>100 days) was
adjusted for narcotic use preoperatively, the number of
ribs resected, estimated blood loss, length of hospital stay,
and surgical technique. All tests were two-sided, with 0.05
serving as the level of significance.
Results
In total, 25 patients underwent the “cut-in patch-out”
approach while 16 patients underwent a traditionalposterolateral thoracotomy and separate chest wall re-
section. Patient characteristics are presented in Table 1.
The two groups were similar with regards to age, gender,
race, preoperative narcotic and tobacco use. The major-
ity of P-NSCLC in both groups involved the left lung
and chest wall. Adenocarcinoma was the most prevalent
pathology in both groups. Due to the increasing use of
induction therapy over time, more patients received neo-
adjuvant therapy who underwent the “cut-in patch-out”
technique (96.0%) as compared to the traditional group
(87.5%) although this did not reach statistical significance.
Perioperative factors were also similar between both
groups (Table 1). All patients underwent anatomic upper
lobectomies with complete peribronchial and medias-
tinal lymph node dissections. No differences were appre-
ciated in the utilization of thoracic epidural catheters,
estimated blood loss, or the number of ribs resected.
Other factors such as tumor size, number of lymph
nodes sampled, nodal status, and R0 resection rates were
similar. While there was a trend for higher N2 disease in
the traditional group, final pathologic staging was statis-
tically similar in both groups. In terms of T4 tumor
Figure 2 Rib disarticulation and hilar dissection. The ribs are disarticulated posteriorly from their respective transverse processes and vertebral
bodies. After chest wall resection is complete, hilar dissection including division of lobar vessels and airways for lobectomy along with complete
peribronchial and mediastinal lymph node dissection is performed through the chest wall defect itself facilitated with the use of endoscopic
stapling devices.
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in both groups.
Postoperative outcomes are presented in Table 2. The
duration of intravenous narcotics was similar for both
groups, with a mean of 6.3 days for the “cut-in patch-
out” group and 6.0 days for the traditional thoracotomy
group. Additionally, average lengths of hospital stay were
also statistically similar at 13.1 days and 12.1, days re-
spectively. While complication rates were slightly higher
in the traditional group, none of these reached statisti-
cally significance. In particular, one patient in each
group developed a wound infection, neither or which re-
quired surgical intervention. Pulmonary complications
including pneumonia, reintubation, tracheostomy, pul-
monary embolism, and bronchopleural fistulae were
similar across both groups. There was no operativemortality with one death in both groups within 90 days
of surgery.
Daily outpatient narcotic use was significantly lower in
the “cut-in patch-out” group (80.6 days versus 158.2 days,
p < 0.01) (Figure 4). With respect to long-term oncologic
outcomes the “cut-in patch-out” group had lower five-
year recurrence rates (24.0% versus 62.5%, p = 0.02) and
improved five-year survival rates (48.0% versus 12.5%, p =
0.04). Finally, systemic recurrence was more common
than local recurrence in both groups.
Results of multivariate regression analysis to identify
risk factors for prolonged oral narcotic use (>100 days)
is given in Table 3. In summary, although there was a
trend towards preoperative narcotic use predicting pro-
longed oral narcotic use, this did not reach statistical sig-
nificance. Additionally, prolonged oral narcotic use was
Figure 3 Chest wall reconstruction. After the specimens are removed, the chest wall defect is closed with a double layer of a Vicryl mesh. The
mesh is initially secured to the transverse processes then to rib edges with interrupted 0-polyproplene sutures reinforced with a running looped
0-polydioxanone suture. Typically the first rib and first transverse process are not included in the patch to avoid contact with the brachial plexus
or subclavian vessels.
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timated blood loss, or length of stay. However, the trad-
itional technique was strongly associated with prolonged
oral narcotic use (OR 8.28, p = 0.01).
Discussion
The results of this study demonstrate that a “cut-in
patch-out” approach to P-NSCLC can offer a reduction
in postoperative pain when compared with a traditional
approach. Although not seen in the immediate post-
operative course with intravenous narcotic use, the
benefit became apparent after discharge analyzing the
duration of oral narcotic requirement by both univariate
and in a multivariate model. From an oncologic stand-
point, the number of mediastinal lymph nodes retrieved
and surgical margin status were similar between the two
groups. More importantly, five-year recurrence rates and
survival were both improved in patients undergoing the
“cut-in patch-out” technique suggesting this approach
offers at least an equivalent oncologic outcome.
A “cut-in patch-out” type of surgical approach to
P-NSCLC, was initially reported by Kent et al. fromMemorial Sloan-Kettering Cancer Center using a polyte-
traflouroethylene patch for chest wall reconstruction in
2004 [10]. We have been using this technique at our insti-
tution dating back to 2001. One limitation to this ap-
proach is that it is only feasible if at least 3 apical ribs are
removed. Optimal exposure to the pulmonary hilum and
mediastinal lymph nodes is however provided if 4 or more
ribs are removed. We believe there is little if any downside
with respect to additional pain or reduction of chest wall
mechanics following upper lobectomy and removal of the
upper 4 ribs to optimize exposure. In the less common
scenario where only one or two ribs require removal, div-
ision of the hilar vessels and airway will usually require a
separate thoracotomy or a VATS-assisted approach. The
use of VATS for P-NSCLC tumors has been reported to
have good preliminary results with cited advantages in-
cluding the ability to assess the subclavian vessels and
hilum minimally invasively [11]. Additionally, a recent re-
port has demonstrated the feasibility of a VATS approach
to perform a limited en bloc resection for a superior sul-
cus resection [12]. Specific advantages to a VATS approach
for P-NSCLC need further study however.
Table 1 Patient and operative characteristics
Characteristic Cut-in patch




Mean age (SD) 56.9 (±9.4) 57.3 (±9.6) 0.90
Female (%) 15 (60.0%) 8 (50.0%) 0.76
Race: White (%) 20 (80.0%) 11 (68.8%) 0.66
Mean Pack Years (SD) 48.6 (±26.4) 44.2 (±29.4) 0.62
Taking Oral Narcotics
Preoperatively
3 (12.0%) 4 (25.0%) 0.40
Neoadjuvant Treatment
Radiation Only (%) 2 (8.0%) 2 (12.5%) 0.64
Chemoradiation (%) 22 (88.0%) 12 (75.0%) 0.40
Location: Left (%) 19 (73.1%) 11 (68.8%) 0.88
Pathology
Adenocarcinoma (%) 13 (52.0%) 8 (50.0%) 0.98
Squamous (%) 9 (36.0%) 7 (43.8%) 0.75
Other (%) 3 (12.0%) 1 (6.3%) 0.98
Epidural pain catheter (%) 14 (56.0%) 9 (56.3%) 0.98
Estimated Blood Loss (SD) 442 (±223) 423 (±256) 0.83
Mean ribs resected (SD) 3.65 (±0.83) 3.38 (±0.51) 0.25
Mean tumor Size in cm (SD) 4.20 (±3.03) 4.71 (±2.14) 0.56
Mean number of nodes
sampled (SD)
14.2 (±5.1) 14.8 (±6.6) 0.75
Positive lymph nodes (%) 2 (8.0%) 4 (25.0%) 0.19
R0 resection 23 (92.0%) 14 (87.5%) 0.64
R1 resection 2 (8.0%) 2 (12.5%)
Final Pathology Staging
≤ T2 3 (12.0%) 2 (12.5%) 0.96
T3 10 (40.0%) 6 (33.3%) 0.87
T4 12 (48.0%) 8 (50.0%) 0.90
Vertebral Body 9 (40.0%) 6 (37.5%) 0.93
Subclavian Vessels 3 (12.0%) 2 (12.5%) 0.96
N0 23 (92.0%) 11 (68.8%) 0.13
N1 1 (4.0%) 1 (6.3%) 0.74
N2 1 (4.0%) 3 (18.8%) 0.31
Categorical data presented as a number (%) while continuous data presented
as mean ± standard deviation unless otherwise stated. p-values represent with
either independent sample t-test or chi-squared as dictated by data type.
Table 2 Post-operative outcomes
Outcome Cut-in patch




Length of stay in days (SD) 13.1 (±7.42) 12.6 (±6.11) 0.82
Mean days on IV narcotics (SD) 6.2 (±3.75) 6.0 (±3.39) 0.86
Morbidity 7 (28.0%) 4 (25.0%) 0.83
Wound Infection 1 (4.0%) 1 (6.3%) 0.74
Pneumonia 4 (16.0%) 3 (18.8%) 0.82
Reintubation 5 (24.0%) 5 (31.3%) 0.65
Tracheostomy 3 (12.0%) 4 (25.0%) 0.51
Pulmonary Embolism 2 (8.0%) 1 (6.3%) 0.83
Bronchopleural Fistula 1 (4.0%) 1 (6.3%) 0.74
Mortality
30-day mortality 0 (0%) 0 (0%) 1.00
90-day mortality 1 (4.0%) 1 (6.3%) 0.97
Mean days on oral
narcotics (SD)
80.6 (±62.4) 158.2 (±119.2) <0.01
Alive at 5 years (%) 12 (48.0%) 2 (12.5%) 0.04
Recurrence at 5 years (%) 6 (24.0%) 10 (62.5%) 0.02
Site of Recurrence
Local (%) 2 (8.0%) 3 (18.8%) 0.36
Distant (%) 4 (16.0%) 7 (43.8%) 0.07
Categorical data presented as a number (%) while continuous data presented
as mean ± standard deviation unless otherwise stated. p-values represent with
either independent sample t-test or chi-squared as dictated by data type.
Figure 4 Scatter-plot distribution demonstrating length of
outpatient oral narcotic requirements of the “cut-in patch-out”
versus traditional techniques. Bar represents mean days of oral
narcotic use.
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reconstruction after P-NSCLC resection including poly-
propylene and polytetrafluoroethylene prosthetic mesh
[3,4,13]. Some authors have described using no patch re-
construction as the scapula typically covers the bony
chest wall defect [10]. We have used a double layer
Vicryl mesh, which does not require removal in case of a
low-grade infection with the added advantage of stabiliz-
ing the cut ribs pending scar tissue replacement. No pa-
tients in our series required Vicryl mesh removal despite
Table 3 Risk factors for duration of oral narcotics >100 days
Odds ratio (95% C.I.) p-value
Taking Narcotics Preoperatively 1.19 (0.02–8.67) 0.38
More than 3 Ribs Resected 1.14 (0.15–2.36) 0.18
Estimated Blood Loss 1.01 (0.98–1.03) 0.13
Length of Stay 1.08 (0.98–1.21) 0.42
Traditional Technique 8.28 (1.54–44.41) 0.01
Multiple regression analysis for prolonged oral narcotic use (>100 days)
following P-NSCLC resection. CI = Confidence Interval.
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which are prone to occur after radiation therapy and
relative soft tissue devascularization after rib removal.
Although previous work has investigated the prevalence
of post-thoracotomy pain, there is little information on
pain after a chest wall resection. One retrospective analysis
of thoracotomy patients by Keller et al. determined that
50% of those undergoing chest wall resections with thora-
cotomy developed significant post-thoracotomy pain com-
pared with 11% of those undergoing thoracotomy without
chest wall resection [14]. A more recent study used a
post-operative questionnaire to assess quality of life after
thoracotomy and found that only 16% of patients were
using narcotics for pain control 3 months after surgery
[6]. This appears to be somewhat lower that our study
where 26.1% of patients in the “cut-in patch-out” group
and significantly lower than 53.8% in the traditional thora-
cotomy group still requiring narcotics at 3 months. These
discrepancies would not be unexpected as the pain associ-
ated with P-NSCLC surgery is undoubtedly worsened by
chest wall resection as well as a separate rib spreading
thoracotomy in the subset of patients undergoing trad-
itional surgery. Of note, an advantage to this current study
is that outpatient narcotic use was measured using a state-
wide electronic narcotic tracking program thereby redu-
cing measurement bias.
The factors that have been shown to be associated
with the best outcomes for P-NSCLC resections include
R0 resections, absence of positive nodes, and anatomic
lobar versus wedge pulmonary resections [15]. Although
these variables were all similar between the groups, there
was a trend towards higher number of positive N2 dis-
ease in the traditional thoracotomy group. This factor,
along with a lower R0 resection rate and lower use of
neoadjuvant therapy early in our series, may have con-
tributed to reduced long-term survival in the traditional
surgery group. Subsequent treatment guidelines set forth
by the NCCN and ACCP have recommend neoadjuvant
chemoradiation therapy followed by a consideration of
surgery so it is not surprising that more patients under-
going the “cut in patch out” technique did receive neo-
adjuvant therapy. After trimodality therapy, five-yearsurvival rates for patients with P-NSCLC have been re-
ported to range between 41% and 59% [16-18].
There are several limitations to this study. First, this is
a small retrospective series at a single institution. Al-
though reduction in oral narcotic requirements were ap-
parent in the “cut-in patch-out” group, larger and more
uniform patient subsets are needed to determine differ-
ences from long-term oncologic perspectives including
the ability to achieve tumor free margins. Another limi-
tation is that although the majority of patients appeared
to be taking similar narcotic doses, we were only able to
determine the use of narcotics per se and could not obtain
accurate dosage information. Additionally, although it ap-
peared that non-narcotic pain medications such as non-
steroidal anti-inflammatory drugs or gamma-aminobutyric
acid analogs were used sparingly in our series, we were
unable to conclusively make this determination for accur-
ate analysis.Conclusions
In conclusion, this study demonstrates that compared
with a traditional approach involving separate thoracot-
omy and chest wall resection for P-NSCLC tumors, a
“cut-in patch-out” technique may reduce outpatient nar-
cotic requirements and appears to result in equivalent
oncologic outcomes including survival rates. We there-
fore believe this approach warrants further investigation.
Furthermore, based on this favorable experience we have
more recently adapted a variation of this “cut-in patch-
out” technique using non-absorbable prosthetic mesh
for select patients with non P-NSCLC and chest wall
invasion.
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